| abstract |
A method for predicting the cardiotoxicity of a compound, said method comprising a) providing a test compound; b) determining the ability of the compound at a concentration of about 10μM to inhibit the kinase activity in the model kinase group consisting of CSF1R, KIT, FYN, PDGFR beta, FGR, LCK, Ephrin Receptor B1, FRK, ABL1, PDGFR alpha, and HCK, wherein inhibition by over 80% of at least one of said kinases indicates a likelihood that said test compound will demonstrate cardiotoxicity. |